Chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Evaluating axicabtagene ciloleucel in the ZUMA-7 trial.

COI Statement

Vadim Lesam has received honoraria from AbbVie; and travel grants from AbbVie, Janssen, Pfizer, and Pierre Fabre. Cristian Munteanu does not have any conflicts of interest.

References:

• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second‐line therapy for large B‐cell lymphoma. N Engl J Med. 2022;386(7):640‐654. https://www.nejm.org/doi/full/10.1056/NEJMoa2116133
• Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B‐cell lymphoma. N Engl J Med. 2023;389(2):148‐157. https://www.nejm.org/doi/full/10.1056/NEJMoa2301665
• Ghobadi A, Munoz J, Westin JR, et al. Outcomes of subsequent antilymphoma therapies after second‐line axicabtagene ciloleucel or standard of care in ZUMA‐7. Blood Adv. 2024;8(11):2982‐2990.
• Locke FL, Oluwole OO, Kuruvilla J, et al. Axicabtagene ciloleucel vs standard of care in second‐line large B‐cell lymphoma: outcomes by metabolic tumor volume. Blood. 2024;143(24):2464‐2473. 10.1182/blood.2023021620
• Kahan BC, Cro S, Doré CJ, et al. Reducing bias in open‐label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15(1):456.